Released Nov 10, 2025, after the close
10-Q filed Nov 10, 2025, 41 days after period end · 0001636422-25-000146
Q3 2025 · 10-Q
Revenue$76.32M$76.32M −0.0% vs Q3 2024−5.4% vs Q2 2025
Net Income-$22.23M-$22.23M N/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.32-$0.32 N/M vs Q3 2024N/M vs Q2 2025
Gross Profit$40,133,000+10.6%
Operating Income-$17,509,000N/M
Operating Cash Flowderived-$464,000N/M
Free Cash Flowderived-$719,000N/M
Margins · derived
Gross margin52.6%+5.1 pt vs Q3 2024
Operating margin-22.9%−5.0 pt vs Q3 2024
Net margin-29.1%−9.8 pt vs Q3 2024
What the release said
The release
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $76.32M | $76.35M | $73.77M | $68.35M |
| Net Income | -$22.23M | -$14.73M | -$22.03M | -$45.74M |
| EPS Diluted | -$0.32 | -$0.24 | -$0.39 | -$0.84 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Health Catalyst, Inc. · CIK 1636422 · Engraved from SEC EDGAR